Details of Disease

General Information of Disease (ID: DIS4GHSB)

• Disease Name: Cerebral edema
• Synonyms: intracranial swelling; wet brain
• Disease Class: 8D60: Increased intracranial pressure
• Definition: Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see hypoxia, brain). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of csf flow (e.g., obstructive hydrocephalus). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)
• Disease Hierarchy:
  DIS6ZC3X: Brain disease
  DIS4GHSB: Cerebral edema
• ICD Code: ICD-11: ICD-11: 8D60.1
• Disease Identifiers:
  MONDO ID: MONDO_0006684
  MESH ID: D001929
  UMLS CUI: C0006114
  MedGen ID: 2337
  HPO ID: HP:0002181
  SNOMED CT ID: 2032001

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 9 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Betamethasone	DMAHJEF	Approved	Small molecular drug	[1]
Cortisone Acetate	DMG8K57	Approved	Small molecular drug	[2]
Dexamethasone	DMMWZET	Approved	Small molecular drug	[3]
Hydrocortisone	DMGEMB7	Approved	Small molecular drug	[4]
Hydroxocobalamin	DMGKV9D	Approved	Small molecular drug	[5]
Mannitol	DMSCDY9	Approved	Small molecular drug	[6]
Methylprednisolone	DM4BDON	Approved	Small molecular drug	[7]
Prednisolone	DMQ8FR2	Approved	Small molecular drug	[8]
Triamcinolone	DM98IXF	Approved	Small molecular drug	[9]

This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
BIIB093	DMHBZTG	Phase 3	NA	[10]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 4 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
MYLK	TT18ETS	Strong	Biomarker	[11]
NTN1	TT0AH4L	Strong	Therapeutic	[12]
PLAU	TTGY7WI	Strong	Biomarker	[13]
S100B	TTQ0V86	Strong	Biomarker	[14]

This Disease Is Related to 1 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
MYL9	OT6B22JB	Strong	Biomarker	[15]

References

• [1] Betamethasone FDA Label
• [2] Cortisone acetate FDA Label
• [3] Dexamethasone FDA Label
• [4] Hydrocortisone FDA Label
• [5] Hydroxocobalamin FDA Label
• [6] Mannitol FDA Label
• [7] Methylprednisolone FDA Label
• [8] Prednisolone FDA Label
• [9] Triamcinolone FDA Label
• [10] ClinicalTrials.gov (NCT02864953) Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction (CHARM). U.S. National Institutes of Health.
• [11] Inhibition of myosin light chain kinase reduces brain edema formation after traumatic brain injury.J Neurochem. 2010 Feb;112(4):1015-25. doi: 10.1111/j.1471-4159.2009.06514.x. Epub 2009 Nov 27.
• [12] Recombinant Netrin-1 binding UNC5B receptor attenuates neuroinflammation and brain injury via PPAR/NFB signaling pathway after subarachnoid hemorrhage in rats. Brain Behav Immun. 2018 Mar;69:190-202. doi: 10.1016/j.bbi.2017.11.012. Epub 2017 Nov 21.
• [13] Massive cerebral edema after recanalization post-thrombolysis.J Neuroimaging. 2001 Oct;11(4):447-51. doi: 10.1111/j.1552-6569.2001.tb00079.x.
• [14] Serum S100B, brain edema, and hematoma formation in a rat model of collagenase-induced hemorrhagic stroke.Brain Res Bull. 2009 Mar 16;78(4-5):158-63. doi: 10.1016/j.brainresbull.2008.10.012. Epub 2008 Nov 21.
• [15] Inhibition of the myosin light chain kinase prevents hypoxia-induced blood-brain barrier disruption.J Neurochem. 2007 Jul;102(2):501-7. doi: 10.1111/j.1471-4159.2007.04506.x. Epub 2007 Apr 10.